A Study of the Drugs Talazoparib and Temozolomide in Prostate Cancer
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Castration Resistant Prostate Cancer
- Prostate Adenocarcinoma
- Prostate Cancer
- Prostate Cancer Metastatic
- Prostate Neoplasm
- Type
- Interventional
- Phase
- Phase 1Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Only males
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04019327
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Karen Autio, MD Memorial Sloan Kettering Cancer Center
Get Well Soon